Clinical trials: Amyotrophic Lateral Sclerosis (ALS)
Alzheimer Disease, Frontotemporal Dementia
Proteinopathies Expression in Skin of Neurodegenerative Disorders
The goal of this observational study is to compare the aggregation pattern of proteinopathies (alpha-synuclein, amyloid-beta, phosphorylated tau and transactive response DNA -binding protein 43 [TDP43]) in skin biopsies of…
- Conditions
- Alzheimer Disease, Frontotemporal Dementia, Parkinson Disease, Atypical Parkinsonism
- Trial name
- NCT06528964
- Testing
- Immunohistochemistry and immunofluorescence
- Where
- Mexico
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Universidad Autonoma de San Luis Potosí
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Assessing Motor Neuron Disease Mechanisms by Threshold Tracking Transcranial Magnetic Stimulation and Magnetic Resonance Spectroscopy
Amyotrophic Lateral Sclerosis (ALS) is a motor neuron disease, which cases the death of neurons controlling the voluntary muscles.
- Conditions
- Amyotrophic Lateral Sclerosis, Motor Neuron Disease, Cortical Excitability
- Trial name
- NCT03664206
- Testing
- MRS, conventional TMS and treshold tracking TMS
- Where
- Denmark
- Volunteers
- healthy volunteers welcome
- Sponsor
- Sándor Beniczky
Amyotrophic Lateral Sclerosis
Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis
The objective of this study is to determine whether creatine slows disease progression in subjects with amyotrophic lateral sclerosis (ALS).
- Trial name
- NCT00005766
- Testing
- Creatinine
- Where
- United States
- Sponsor
- National Center for Research Resources (NCRR)
Amyotrophic Lateral Sclerosis
Early Access Program for Ulefnersen in Children, Adolescents and Adults With FUS-associated Amyotrophic Lateral Sclerosis (FUS-ALS)
This expanded access program provides access to ulefnersen for eligible patients with FUS-associated amyotrophic lateral sclerosis (FUS-ALS) who meet protocol-defined eligibility criteria.
- Trial name
- NCT07862959
- Testing
- Ulefnersen
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Amyotrophic Lateral Sclerosis (ALS), Motor Neuron Disease (MND)
Healing ALS Registry Observational Study (HAROS)
This is a prospective, observational, online study of people diagnosed with ALS, MND or PLS referred to as HAROS (Healing ALS Registry Observational Study).
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Motor Neuron Disease (MND), Primary Lateral Sclerosis (PLS)
- Trial name
- HAROS (NCT07233148)
- Testing
- Education about treatment options, Dietary Supplements: Vitamins, Minerals, Herbs, etc., Meditation, Prayer, Talk Therapy, Affirmations, Journaling, etc.
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Healing Advocates Registry and Ministry
Post-stroke, Parkinson Disease
Evaluation of the Impact of Virtual Park on Training Motivation in Adult Patients
The purpose of this clinical study is to evaluate the feasibility, usability, and motivational impact of VirtualPark, a virtual reality-based dual-task rehabilitation system, in adults with neurological and age-related…
- Conditions
- Post-stroke, Parkinson Disease, Amyotrophic Lateral Sclerosis, Mild Cognitive Impairment (MCI)
- Trial name
- VP_Adults (NCT07616050)
- Testing
- Dual-task training with Virtual Reality, Cycling training
- Where
- 7 sites in Italy
- Volunteers
- 70 people
- Sponsor
- Marta Mondellini
Amyotrophic Lateral Sclerosis (ALS)
Circulating Biomarker for Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis (ALS) is a rare disease with a worldwide incidence of 2-3 cases per 100,000 individuals/year and it is characterized by progressive neurodegeneration of motor neurons.
- Trial name
- NCT03088839
- Where
- Italy
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Neuromed IRCCS
Amyotrophic Lateral Sclerosis (ALS)
Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)
This is a long-term, double-blind, placebo-controlled study of MCI-186 to treat ALS. This study is the long-term extension of Study NCT00330681; Study NCT00330681 is a Phase 3, randomized, double-blind, placebo control, parallel…
- Trial name
- NCT00424463
- Testing
- MCI-186
- Where
- Japan
- Volunteers
- 181 people
- Sponsor
- Shionogi
Social Cognition
Social Cognition in Patients With Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis, also known as Charcot disease, is a neurodegenerative disease evidenced by gradual paralysis of the muscles involved in voluntary motor function.
- Trial name
- COSISLA (NCT04406675)
- Testing
- neuropsychological test
- Where
- France
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- University Hospital, Angers
Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD)
This is an OLE study conducted to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and clinical effects of WVE-004 in adult participants with ALS, FTD, or mixed ALS/FTD phenotype with a documented…
- Trial name
- NCT05683860
- Testing
- WVE-004 10 mg Q12W
- Where
- 3 sites in Netherlands, United Kingdom
- Volunteers
- 8 people
- Sponsor
- Wave Life Sciences USA, Inc.
Amyotrophic Lateral Sclerosis
Neural Stem Cell Treatment for Amyotrophic Lateral Sclerosis (STEMALS)
A Not for Profit Phase II Study to Evaluate Safety, Efficacy and Biomarkers secondary endpoints of Human Neural Stem cell intracerebroventricular transplantation in amyotrophic lateral sclerosis patients: a randomized, placebo…
- Trial name
- STEMALS (NCT06344260)
- Testing
- human Neural Stem Cells (hNSC)
- Where
- 4 sites in Italy
- Volunteers
- 30 people
- Sponsor
- Casa Sollievo della Sofferenza IRCCS
Amyotrophic Lateral Sclerosis
Assessment of Postural Orientation and Equilibrium In Early Amyotrophic Lateral Sclerosis (ALS)
The purpose of this pilot study is to characterize changes in postural orientation and equilibrium in early diagnosed ALS patient.
- Trial name
- NCT00956501
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Amyotrophic Lateral Sclerosis (ALS)
Remotely Supervised tDCS for Slowing ALS Disease Progression
Most ALS care is centered on patient support and symptom management, making rehabilitation an integral aspect for slowing disease progression, prolonging life span, and increasing quality of life.
- Trial name
- NCT04866771
- Testing
- Transcranial Direct Current Stimulation (tDCS)
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Illinois Chicago
Nutritional Deficiency, Neuro-Degenerative Disease
Nutritional Prognostic Factors in ALS
Background. Several nutritional factors have been evaluated as prognostic factors for survival in ALS patients at earlier stages of the disease [body mass index (BMI), body composition expressed as fat free mass (FFM), fat mass…
- Conditions
- Nutritional Deficiency, Neuro-Degenerative Disease, Gastrostomy
- Trial name
- PEG-ALS (NCT03487536)
- Testing
- Nutritional assessment
- Where
- Italy
- Volunteers
- 47 people
- Sponsor
- University of Bari
Amyotrophic Lateral Sclerosis
Therapeutic Nanocatalysis to Slow Disease Progression of Amyotrophic Lateral Sclerosis (ALS)
The objective of this trial was to assess the efficacy, safety, and PK/PD effects of CNM-Au8 as a disease-modifying agent for the treatment of ALS by utilizing electrophysiological measures to detect preservation of motor neuron…
- Trial name
- RESCUE-ALS (NCT04098406)
- Testing
- CNM-Au8
- Where
- 2 sites in Australia
- Volunteers
- 45 people
- Sponsor
- Clene Nanomedicine
Amyotrophic Lateral Sclerosis, Neurodegenerative Disease
Pennsylvania Consortium: Clinical Database
In order to streamline disease research in ALS and other motor neuron diseases, we have joined a consortium of clinical centers (Hershey and University of Pittsburgh) who will collaborate on clinical and basic research projects.
- Conditions
- Amyotrophic Lateral Sclerosis, Neurodegenerative Disease, Motor Neuron Disease
- Trial name
- NCT00718445
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Drexel University College of Medicine
Amyotrophic Lateral Sclerosis (ALS)
Personalized Antisense Oligonucleotide Therapy for a Participant With TARDBP ALS
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in TARDBP.
- Trial name
- NCT07703462
- Testing
- nL-TARDB-002
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- n-Lorem Foundation
Amyotrophic Lateral Sclerosis
Exploratory Study of Biotelemetry in Amyotrophic Lateral Sclerosis
Study 201283 is an exploratory, non-controlled, non-drug study in Amyotrophic Lateral Sclerosis (ALS) subjects. This study is being conducted as the first step for developing new meaningful measure(s) which might prove to be more…
- Trial name
- NCT02447952
- Testing
- Faros Sensor (FS) and LifeInsight Hub, Fast Fix electrode patch, Quantitative Measure of Speech (Core Phase Only)
- Where
- 2 sites in United Kingdom
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Motor Neuron Disease, Familial, Amyotrophic Lateral Sclerosis With Dementia
Cortico-Spinal tDCS as Rehabilitative Intervention in Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) is a motor neuron disease, which is a group of neurological disorders that selectively affect motor neurons, the cells that control voluntary muscles of the body.
- Trial name
- tDCS_MND_2 (NCT04293484)
- Testing
- Anodal bilateral motor cortex and cathodal spinal tDCS
- Where
- Italy
- Volunteers
- 31 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Amyotrophic Lateral Sclerosis
Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)
The purpose of this research study is to evaluate the safety and effectiveness of CK-2017357 when taken with or without riluzole (also called Rilutek®) in patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT01709149
- Testing
- CK-2017357, Riluzole
- Where
- 75 sites in United States, Canada and 6 more
- Volunteers
- 711 people
- Sponsor
- Cytokinetics